AR110017A1 - Anticuerpos de pd-1 y usos de estos - Google Patents
Anticuerpos de pd-1 y usos de estosInfo
- Publication number
- AR110017A1 AR110017A1 ARP170103027A ARP170103027A AR110017A1 AR 110017 A1 AR110017 A1 AR 110017A1 AR P170103027 A ARP170103027 A AR P170103027A AR P170103027 A ARP170103027 A AR P170103027A AR 110017 A1 AR110017 A1 AR 110017A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence selected
- lcdr1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Reivindicación 1: Un anticuerpo aislado que se une a la proteína de muerte programada 1 (PD-1), en donde el anticuerpo se une a un epítopo que comprende los aminoácidos 126 a 136 de PD-1 humana, en donde los aminoácidos 126 a 136 se numeran de acuerdo con la SEQ ID Nº 1. Reivindicación 11: Un anticuerpo que se une a la proteína de muerte programada l (PD-1), el que comprende: i) (a) HCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 5, (b) HCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 6, (c) HCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 7, (d) LCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 9, (e) LCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 10 y (f) LCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 11, o ii) (a) HCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 13, (b) HCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 14, (c) HCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 15, (d) LCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 17, (e) LCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 18 y (f) LCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 19, o iii) (a) HCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 21, (b) HCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 22, (c) HCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 23, (d) LCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 25, (e) LCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 26 y (f) LCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 27, o iv) (a) HCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 29, (b) HCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 30, (c) HCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 31, (d) LCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 33, (e) LCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 34 y (f) LCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 35, o v) (a) HCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 37, (b) HCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 38, (c) HCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 39, (d) LCDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 41, (e) LCDR2 que comprende la secuencia de aminoácidos de la SEQ ID Nº 42 y (f) LCDR3 que comprende la secuencia de aminoácidos de la SEQ ID Nº 43, o vi) (a) HCDR1 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 45, 53, 61, 69, 77, 85, 93, 101, 109 y 117, (b) HCDR2 que comprende una 5 secuencia de aminoácidos seleccionada de las SEQ ID Nº 46, 54, 62, 70, 78, 86, 94, 102, 110 y 118, (c) HCDR3 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 47, 55, 63, 71, 79, 87, 95, 103, 111 y 119, (d) LCDR1 que comprende una secuencia de aminoácidos 10 seleccionada de las SEQ ID Nº 49, 57, 65, 73, 81, 89, 97, 105, 113 y 121, (e) LCDR2 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 50, 58, 66, 74, 82, 90, 98, 106, 114 y 122, y (f) LCDR3 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 51, 15 59, 67, 75, 83, 91, 99, 107, 115 y 123, o vii) (a) HCDR1 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 125, 133, 141, 149, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, 269, 277 y 285, (b) HCDR2 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 126, 134, 142, 150, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, 270, 278 y 286, (c) HCDR3 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 127, 135, 143, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, 271, 279 y 287, (d) LCDR1 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 129, 137, 145, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273, 281 y 289, (e) LCDR2 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 130, 138, 146, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274, 282 y 290, y (f) LCDR3 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 131, 139, 147, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, 267, 275, 283 y 291, o viii) (a) HCDR1 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 293, 301, 309 y 317, (b) HCDR2 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 294, 302, 310 y 318, (c) HCDR3 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 295, 303, 311 y 319, (d) LCDR1 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 297, 305, 313 y 321, (e) LCDR2 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 298, 306, 314 y 322, y (f) LCDR3 que comprende una secuencia de aminoácidos seleccionada de las SEQ ID Nº 299, 307, 315 y 323. Reivindicación 44: Un ácido nucleico aislado que codifica el anticuerpo de cualquiera de las reivindicaciones que anteceden. Reivindicación 50: Una composición farmacéutica que comprende el anticuerpo anti-PD-1 de cualquiera de las reivindicaciones 1 a 43 y un portador farmacéuticamente aceptable. Reivindicación 51: Un método para el tratamiento del cáncer en un mamífero que comprende la administración de una cantidad eficaz del anticuerpo anti-PD-1 de cualquiera de las reivindicaciones 1 a 43, o una composición farmacéutica de la reivindicación 50.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662416602P | 2016-11-02 | 2016-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110017A1 true AR110017A1 (es) | 2019-02-13 |
Family
ID=60543661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170103027A AR110017A1 (es) | 2016-11-02 | 2017-11-01 | Anticuerpos de pd-1 y usos de estos |
Country Status (29)
Country | Link |
---|---|
US (3) | US10654929B2 (es) |
EP (2) | EP3535298B1 (es) |
JP (2) | JP7086066B2 (es) |
KR (1) | KR20190088480A (es) |
CN (1) | CN110392694B (es) |
AR (1) | AR110017A1 (es) |
AU (1) | AU2017355401A1 (es) |
BR (1) | BR112019008494A2 (es) |
CA (1) | CA3039992A1 (es) |
CY (1) | CY1124730T1 (es) |
DK (1) | DK3535298T3 (es) |
ES (1) | ES2898025T3 (es) |
HR (1) | HRP20211703T1 (es) |
HU (1) | HUE057559T2 (es) |
IL (1) | IL266259A (es) |
LT (1) | LT3535298T (es) |
MA (1) | MA46708B1 (es) |
MD (1) | MD3535298T2 (es) |
MX (1) | MX2019004834A (es) |
MY (1) | MY195110A (es) |
PL (1) | PL3535298T3 (es) |
PT (1) | PT3535298T (es) |
RS (1) | RS62589B1 (es) |
RU (1) | RU2761640C2 (es) |
SG (1) | SG11201903857UA (es) |
SI (1) | SI3535298T1 (es) |
TW (2) | TW202321301A (es) |
WO (1) | WO2018085358A1 (es) |
ZA (1) | ZA201902455B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
TWI773647B (zh) * | 2015-06-23 | 2022-08-11 | 史隆凱特林紀念癌症中心 | 新穎pd-1免疫調控劑 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
AU2017355401A1 (en) | 2016-11-02 | 2019-05-02 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
US11702458B2 (en) | 2017-01-05 | 2023-07-18 | Kahr Medical Ltd. | PD1-41BBL fusion protein and methods of use thereof |
SI3565828T1 (sl) | 2017-01-05 | 2022-04-29 | Kahr Medical Ltd. | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo |
WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
CR20200099A (es) | 2017-08-03 | 2020-07-24 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
EP4219559A3 (en) | 2017-12-22 | 2023-10-18 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
CR20200330A (es) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anticuerpos anti-pd-1 y métodos de tratamiento |
US11564995B2 (en) * | 2018-10-29 | 2023-01-31 | Wisconsin Alumni Research Foundation | Peptide-nanoparticle conjugates |
KR20220030956A (ko) | 2019-07-05 | 2022-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료 |
WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
CN110669108A (zh) * | 2019-09-06 | 2020-01-10 | 中国药科大学 | 一种多肽及其应用 |
CN110590959B (zh) * | 2019-09-19 | 2021-01-05 | 北京伟杰信生物科技有限公司 | 重组犬pd-1融合蛋白及其制备方法与应用 |
JP2022554270A (ja) | 2019-11-05 | 2022-12-28 | ジョンス セラピューティクス, インコーポレイテッド | 抗pd-1抗体による癌を治療する方法 |
CN110964111B (zh) * | 2019-12-25 | 2020-07-24 | 北京东方百泰生物科技有限公司 | 一种抗pd-l1单克隆抗体、其抗原结合片段及其应用 |
CN111175489B (zh) * | 2020-01-03 | 2021-03-30 | 山西大学 | 磁珠评价免疫检查点分子阻断性抗体阻断活性方法 |
US11692038B2 (en) * | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
IL299238A (en) * | 2020-06-23 | 2023-02-01 | Kadmon Corp Llc | ANTI-PD-1 antibodies and fusion proteins |
CN114316022A (zh) * | 2020-09-30 | 2022-04-12 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
KR102450914B1 (ko) | 2022-03-23 | 2022-10-06 | 재단법인 경북아이티융합 산업기술원 | 차량 간 통신 기반 차량 무선 업데이트 방법 및 시스템 |
WO2024077069A1 (en) * | 2022-10-05 | 2024-04-11 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
CN116854820B (zh) * | 2023-06-26 | 2024-02-06 | 华中科技大学同济医学院附属协和医院 | Pd-1非阻断性清除抗体及其用途 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
FI2206517T3 (fi) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
SI1678314T1 (sl) | 2003-10-22 | 2013-01-31 | Keck Graduate Institute | Metode za sintetiziranje heteromultimernih polipeptidov pri kvasovkah s strategijo razmnoĺ˝evanja haploidnih celic |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
JP2008528033A (ja) | 2005-01-27 | 2008-07-31 | ファイブ プライム セラピューティクス, インコーポレイテッド | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
LT2439273T (lt) * | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
KR101508390B1 (ko) * | 2006-06-06 | 2015-04-08 | 크루셀 홀란드 비.브이. | 포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
EP2119780B1 (en) | 2007-01-24 | 2015-03-25 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
US9783578B2 (en) | 2010-06-25 | 2017-10-10 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP4219805A1 (en) | 2010-07-16 | 2023-08-02 | Adimab, LLC | Antibody libraries |
CA2868883C (en) | 2012-03-30 | 2022-10-04 | Sorrento Therapeutics Inc. | Fully human antibodies that bind to vegfr2 |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
WO2014066834A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
WO2014124217A1 (en) | 2013-02-07 | 2014-08-14 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
EP2972373B1 (en) | 2013-03-15 | 2019-10-09 | F.Hoffmann-La Roche Ag | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
PE20151594A1 (es) | 2013-03-15 | 2015-11-19 | Bristol Myers Squibb Co | Inhibidores de indolamina 2-3 dioxigenasa |
RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
RS59480B1 (sr) * | 2013-12-12 | 2019-12-31 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US20170266270A1 (en) * | 2014-05-13 | 2017-09-21 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
PT3177644T (pt) | 2014-08-05 | 2021-01-13 | MabQuest SA | Reagentes imunológicos que se ligam a pd-1 |
US10800830B2 (en) | 2014-08-08 | 2020-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
MX2017006571A (es) | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
US10239942B2 (en) * | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
HUE059788T2 (hu) | 2015-10-02 | 2022-12-28 | Symphogen As | PD-1 elleni antitestek és készítmények |
CN105153315B (zh) * | 2015-10-09 | 2019-04-02 | 重庆精准生物技术有限公司 | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 |
AU2017208819B2 (en) | 2016-01-22 | 2023-10-19 | MabQuest SA | PD1 specific antibodies |
CN105601752B (zh) * | 2016-02-01 | 2019-08-23 | 海门郝怡雅医药科技有限公司 | 一种多基因重组嵌合抗原受体分子 |
CA3037407C (en) | 2016-09-21 | 2022-10-18 | Cstone Pharmaceuticals | The novel monoclonal antibodies to programmed death 1 (pd-1) |
AU2017355401A1 (en) | 2016-11-02 | 2019-05-02 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
JP7110369B2 (ja) | 2018-02-23 | 2022-08-01 | ユーキュア・(ベイジン)・バイオファーマ・カンパニー・リミテッド | 抗pd-1抗体及びその用途 |
-
2017
- 2017-11-01 AU AU2017355401A patent/AU2017355401A1/en active Pending
- 2017-11-01 KR KR1020197015546A patent/KR20190088480A/ko active IP Right Grant
- 2017-11-01 MX MX2019004834A patent/MX2019004834A/es unknown
- 2017-11-01 DK DK17808224.4T patent/DK3535298T3/da active
- 2017-11-01 SI SI201730970T patent/SI3535298T1/sl unknown
- 2017-11-01 RU RU2019116653A patent/RU2761640C2/ru active
- 2017-11-01 WO PCT/US2017/059481 patent/WO2018085358A1/en active Application Filing
- 2017-11-01 EP EP17808224.4A patent/EP3535298B1/en active Active
- 2017-11-01 TW TW111135407A patent/TW202321301A/zh unknown
- 2017-11-01 TW TW106137769A patent/TWI781120B/zh active
- 2017-11-01 PL PL17808224T patent/PL3535298T3/pl unknown
- 2017-11-01 BR BR112019008494A patent/BR112019008494A2/pt unknown
- 2017-11-01 JP JP2019522464A patent/JP7086066B2/ja active Active
- 2017-11-01 AR ARP170103027A patent/AR110017A1/es unknown
- 2017-11-01 MD MDE20191012T patent/MD3535298T2/ro unknown
- 2017-11-01 CA CA3039992A patent/CA3039992A1/en active Pending
- 2017-11-01 EP EP21188197.4A patent/EP3988569A1/en active Pending
- 2017-11-01 MY MYPI2019002012A patent/MY195110A/en unknown
- 2017-11-01 US US15/800,346 patent/US10654929B2/en active Active
- 2017-11-01 MA MA46708A patent/MA46708B1/fr unknown
- 2017-11-01 HU HUE17808224A patent/HUE057559T2/hu unknown
- 2017-11-01 CN CN201780075562.4A patent/CN110392694B/zh active Active
- 2017-11-01 PT PT178082244T patent/PT3535298T/pt unknown
- 2017-11-01 SG SG11201903857UA patent/SG11201903857UA/en unknown
- 2017-11-01 LT LTEPPCT/US2017/059481T patent/LT3535298T/lt unknown
- 2017-11-01 RS RS20211407A patent/RS62589B1/sr unknown
- 2017-11-01 HR HRP20211703TT patent/HRP20211703T1/hr unknown
- 2017-11-01 ES ES17808224T patent/ES2898025T3/es active Active
-
2019
- 2019-04-17 ZA ZA201902455A patent/ZA201902455B/en unknown
- 2019-04-28 IL IL266259A patent/IL266259A/en unknown
-
2020
- 2020-04-10 US US16/845,805 patent/US11384147B2/en active Active
-
2021
- 2021-11-18 CY CY20211100998T patent/CY1124730T1/el unknown
-
2022
- 2022-01-31 JP JP2022012966A patent/JP2022070873A/ja active Pending
- 2022-06-07 US US17/834,237 patent/US11905329B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina |